[Immunotherapy of pulmonary tuberculosis].

Area of Science:

• Immunology
• Pulmonology
• Pharmacology

Background:

• Destructive tuberculosis presents significant treatment challenges.
• Immunomodulatory agents are explored to enhance therapeutic outcomes.
• Understanding the role of immune correctors in tuberculosis management is crucial.

Purpose of the Study:

• To comparatively analyze the efficacy of different immune correctors in treating destructive tuberculosis.
• To identify the most effective immunocorrector regimen for patients with destructive tuberculosis.
• To evaluate the impact of immune corrector therapy on lung tissue healing and residual changes.

Main Methods:

• A comparative analysis involving 553 patients with destructive tuberculosis.
• Treatment groups included thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon.
• Evaluation of treatment benefits, timing of efficacy, and impact on lung fibrosis and residual changes.

Main Results:

• Early therapeutic benefits were observed with immunocorrector treatment as part of complex therapy.
• The combination of thymogen and interferon yielded the best therapeutic results.
• The efficacy of thymogen and interferon was more pronounced following the healing of lung fibrous deformity, but this was followed by residual changes.

Conclusions:

• Immune correctors can provide early benefits in the complex treatment of destructive tuberculosis.
• The combination of thymogen and interferon appears to be the most effective immunomodulatory approach.
• Further research is needed to mitigate residual changes after successful treatment of lung fibrosis.